Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering
Mistry S, Gouripeddi R, Raman V, Facelli JC
Diabetologia. 2022 Nov 30.
Leggi
Breaking news
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, et al.
Lancet. 2022;400(10366):1869-1881.
Leggi
Comparison of sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist prescribing in patients with diabetes mellitus with and without cardiovascular disease
Gay HC, Yu J, Persell SD, et al.
Am J Cardiol. 2022;S0002-9149(22)01131-6.
Leggi
Fully closed-loop insulin delivery in patients undergoing pancreatic surgery
Krutkyte G, Roos J, Schuerch D, et al.
Diabetes Technol Ther. 2022 Nov 30.
Leggi
KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group
Kidney Int. 2022;102(5S):S1-S127.
Leggi
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease – analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin
Corbin KD, Dagogo-Jack S, Cannon CP, et al.
Diabetes Obes Metab. 2022 Nov 17.
Leggi
A randomized crossover pilot study evaluating glucose control during exercise initiated 1 or 2h after a meal in adults with type 1 diabetes treated with an automated insulin delivery system.
Myette-Cote E, Molveau J, Wu Z, et al.
Diabetes Technol Ther. Pub. online 18 Nov 2022.
Leggi
Mediating effects of technology-based therapy on the relationship between socioeconomic status & glycemic management in pediatric type 1 diabetes
Stanley JR, Clarke A, Shulman R, Mahmud F
Diabetes Technol Ther. Pub. online 21 Nov 2022.
Leggi
The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes
Ferrannini E, Mari A, Monaco GSF, et al.
Diabetologia. 2022 Dec 2.
Leggi
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Morton JI, Marquina C, Shaw JE et, al.
Diabetologia. Pub. online 21 Nov 2022.
Leggi